Group 1 - The core point of the article is that Aorite has received a drug registration certificate for a combined packaging of estradiol tablets and estradiol/dydrogesterone tablets from the National Medical Products Administration [2] Group 2 - Aorite's wholly-owned subsidiary, Yangzhou Aorite Pharmaceutical Co., Ltd., is the entity that received the approval [2]

Core Viewpoint - Fujifilm announced on November 25 that it has received the GMP compliance inspection result notification from the Jiangsu Provincial Drug Administration, confirming that its active pharmaceutical ingredient, Apatinib Mesylate, meets GMP standards, laying a solid foundation for future commercialization [1] Group 1 - The company has successfully passed the GMP compliance inspection for its raw material drug Apatinib Mesylate [1] - This compliance is crucial for the subsequent commercialization of the product [1]

Core Viewpoint - Fujifilm announced on November 25 that it is a major manufacturer of alpha-lipoic acid series products, alongside Tonghe Pharmaceutical, and expects a 5.47% year-on-year increase in the shipment volume of its core product, granular alpha-lipoic acid, in the first half of 2025 due to proactive market expansion strategies and flexible pricing policies [1]. Company Summary - Fujifilm is actively expanding its market presence and implementing flexible pricing strategies to enhance its product competitiveness [1]. - The company anticipates a growth in shipment volume of granular alpha-lipoic acid, indicating a positive outlook for its core product line [1]. Industry Summary - The alpha-lipoic acid market is characterized by significant competition, with Fujifilm and Tonghe Pharmaceutical being key players in the export segment [1]. - The expected growth in shipment volume reflects a broader trend of increasing demand for alpha-lipoic acid products in the market [1].

Core Viewpoint - The company, Anglikang (002940), announced plans to issue A-shares to specific investors to raise 1.16 billion yuan for innovative drug research and industrialization projects [1] Group 1 - The company aims to raise funds amounting to 1.16 billion yuan through a targeted A-share issuance [1] - The raised funds will be allocated specifically for innovative drug development and industrialization projects [1]

Core Viewpoint - The company, Anglikang (002940.SZ), has announced a plan to issue A-shares to specific investors in 2025, aiming to raise 1.16 billion yuan for innovative drug research and industrialization projects [1] Group 1 - The company plans to issue shares to no more than 35 specific investors [1] - The issuance price will be no less than 80% of the average stock price over the 20 trading days prior to the pricing benchmark [1] - The total number of shares issued will not exceed 30% of the company's total share capital before the issuance, amounting to a maximum of 60.5185 million shares [1] Group 2 - The total funds to be raised through this issuance are set at 1.16 billion yuan [1] - The funds will be allocated specifically for "innovative drug research and industrialization projects" [1]

智通财经APP讯，昂利康(002940.SZ)披露2025年度向特定对象发行A股股票预案，公司拟向不超过35名 (含)特定对象发行股票，发行价格不低于定价基准日前二十个交易日公司股票均价的80%，数量按照募 集资金总额除以发行价格确定，且不超过本次发行前公司总股本的30%，即不超过6051.85万股(含本 数)。拟募集资金11.6亿元，用于"创新药研发及产业化项目"。 ...

昂利康公告称，公司召开第四届董事会第十五次会议，审议多项议案。公司拟向特定对象发行A股股 票，发行数量不超60,518,455股，募集资金11.6亿元，用于创新药研发及产业化项目。发行股票种类为A 股，每股面值1元，定价基准日为发行期首日。发行对象不超35名，限售期6个月。本次发行方案尚需提 交股东会审议批准，经深交所审核通过和证监会同意注册后方可实施。此外，公司将于2025年12月16日 召开第三次临时股东会。 ...

Core Viewpoint - The company, Prolo Pharmaceutical, announced that its drug, Dihydrosulfonic Acid Adenosylmethionine Enteric-Coated Tablets, is expected to be approved in November 2024 and is currently expanding its market presence in the Beijing-Tianjin-Hebei "3+N" alliance and Guangdong alliance [1] Group 1 - The drug is set to receive approval in November 2024 [1] - The company has already won bids in the Beijing-Tianjin-Hebei "3+N" alliance and Guangdong alliance [1] - The company is in the process of rapidly expanding its market [1]

Core Viewpoint - Yifan Pharmaceutical (002019) has confirmed that its self-developed project Yilishu has recognized intangible assets and made impairment provisions for the fiscal year 2023, with no impairment signs detected so far [1] Group 1 - The company has reported that its ongoing research project F-652 is still in the development process and has not shown any signs of impairment this year [1]

Group 1 - The number of shareholders for Laimei Pharmaceutical as of November 20 is 30,614, a decrease of 4,399 from the previous period (November 10), representing a decline of 12.56%. This marks the third consecutive period of decline in shareholder numbers [2] - As of the latest closing price, Laimei Pharmaceutical's stock price is 5.01 yuan, reflecting an increase of 2.04%. Since the concentration of shares began, the stock price has cumulatively risen by 0.80%, with 5 days of increases and 6 days of decreases [2] - The latest margin trading data shows that as of November 24, the total margin balance for the stock is 200 million yuan, with a financing balance of 200 million yuan. During the current concentration period, the financing balance has decreased by 6.0383 million yuan, a decline of 2.93% [2] Group 2 - According to the company's third-quarter report, Laimei Pharmaceutical achieved a total operating revenue of 581 million yuan in the first three quarters, a year-on-year decrease of 4.06%. The net profit for the same period is -45.9172 million yuan, a year-on-year decline of 73.82%, with basic earnings per share at -0.0435 yuan [2]